Vol 20, Supp. A (2024)
Case report
Published online: 2024-10-03
Treatment of advanced skin melanoma with BRAF V600 mutation with central nervous system metastases with encorafenib in combination with binimetinib
DOI: 10.5603/ocp.102695
Abstract
A case report of an 80-year-old patient treated with encorafenib and binimetinib due to metastatic melanoma to
the brain, lungs, lymph nodes and subcutaneous tissue. Due to use of the latest forms of systemic therapy in
combination with local therapy, the patient obtained a definite clinical benefit from the therapy. The presented
data correlate with the results described in the literature.
Keywords: case reportmelanomaencorafenibbinimetynibbrain metastases
References
- Gutzmer R, Vordermark D, Hassel J, et al. Melanoma brain metastases – Interdisciplinary management recommendations 2020. Cancer Treatment Reviews. 2020; 89: 102083.
- Phadke M, Ozgun A, Eroglu Z, et al. Melanoma brain metastases: Biological basis and novel therapeutic strategies. Experimental Dermatology. 2021; 31(1): 31–42.
- Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Management of melanoma metastases in the brain. Oncol Clin Pract. 2019; 15(1).
- Holbrook K, Lutzky J, Davies MA, et al. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer. 2020; 126(3): 523–530.
- Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017; 18(7): 863–873.
- Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021; 22(12): 1692–1704.